Insilico Medicine
Insilico Medicine ("Insilico") is a global, clinical stage, end-to-end, generative artificial intelligence (AI)-driven biotech company responsible for advancing the first generative AI-discovered and generative AI-designed drug to human clinical trials.
Insilico Medicine was one of the first groups to publish a method that uses a deep adversarial model for new compound generation. Then, Insilico developed and validated multiple approaches and features for its generative adversarial network (GAN)-based AI platform and integrated those algorithms into the commercially available Pharma.AI platform which works across biology, chemistry, and clinical medicine to identify novel targets and disease hypotheses and to propose novel drug candidates. Using this platform, Insilico has produced a diversified internal pipeline consisting of 31 programs for 29 drug targets, including in fibrosis, cancer, immunology and aging-related disease – including 7 in clinical stages.
The company's lead drug, INS018_055, is a small-molecule drug designed to treat fibrosis-related indications including idiopathic pulmonary fibrosis and the first generative AI-designed drug for an AI-discovered target (TNIK) to reach Phase II trials with patients. The story of this lead drug can be found in a recent publication in Nature Biotechnology, along with extensive data and a customized chatbot for exploring its findings.

More than 40 pharmaceutical companies use Insilico's technology to advance their programs and several are advancing Insilico's AI-designed drugs, and academic researchers have partnered with Insilico to use the company's AI platform to accelerate new treatments for ALS, Alzheimer's disease, and "undruggable" cancer targets.

Insilico Medicine has raised over $400 million in funding. Investors include: Prosperity7 (Aramco's growth venture fund), B Capital Group, Warburg Pincus, BHR Partners, Qiming Ventures, Deerfield, Pavilion Capital, BOLD Capital, Eight Roads, Lilly Asia Ventures, Sinovation Ventures, CPE, OrbiMed, Mirae Asset Capital, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
Welcome to
"Coding the Impossible Cure"
a documentary that captures our 4-year journey of using generative AI to advance a novel drug from concept to Phase II clinical trials.
This process is detailed in our paper, "A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models," published in Nature Biotechnology. The paper highlights our innovative use of generative AI in drug discovery, extensive in vivo and in vitro validation, and Phase I study results, supporting the potential for this technology to produce safe and effective new drugs—potentially the first AI-developed drug to reach the market.
Access to raw footage used in this documentary
Please contact Larry Zhang at for the password.
Executive Team
Alex Zhavoronkov, PhD
Founder and CEO
Areas of expertise:
Generative AI in medicine, ChatGPT in medicine, AI in aging and disease

→ Read Bio
Feng Ren, PhD
Chief Scientific Officer and co-CEO
Hong Kong
AI drug research and development
→ Read Bio
Alex Aliper, PhD
AI drug development
Expanding AI drug research and development in Middle East
Michelle Chen, PhD
Chief Business Officer
AI-designed pharmaceutical assets
Partnering with pharma
Petrina Kamya, PhD
Head of AI Platforms
President of Insilico Medicine Canada
Harnessing AI for Target Discovery & Drug Design
Sujata Rao, MD
Chief Medical Officer
Clinical development strategy.
Fast-tracking novel drugs to patients in need
Global Presence
Insilico Medicine is a global organization with headquarters in Boston and Hong Kong, and offices and labs in Montreal, Shanghai, Suzhou, and Abu Dhabi.
In January 2023, Insilico announced the opening of Life Star, a 6th generation generative AI robotics laboratory located in Suzhou's BioBAY Industrial Park. The fully automated laboratory performs target discovery, compound screening, precision medicine generation and translational research.
In February 2023, Insilico announced the opening of the largest AI-powered biotech center in the Middle East, the Insilico Medicine AI and Quantum Computing Research and Development Center, located in the International Renewable Energy Agency (IRENA) headquarters in Abu Dhabi.
Our mission is to extend healthy productive longevity by transforming drug discovery and development with generative artificial intelligence, significantly reducing the time and cost to bring life-saving medications to patients
PHARMA.AI is the only generative AI-powered drug discovery and development platform that provides end-to-end drug discovery and development services
The platform consists of three components: PandaOmics (for target discovery), Chemistry42 (for molecular synthesis) and inClinico (for clinical trial prediction and optimization). The platform was used to develop Insilico's internal pipeline of 31 programs across 29 drug targets, seven of which are clinical stage, and one, INS018_055 for Idiopathic Pulmonary Fibrosis (IPF), in Phase II trials.
Enabling multi-omics target discovery and deep biology analysis engine to considerably reduce required time from several months to the span of just a few clicks
Find novel lead-like molecules in a week through this automated, machine learning de-novo drug design and scalable engineering platform
Predict clinical trials success rate, recognize the weak points in trial design, while adopting the best practices in the industry
Discover and Prioritize
Design and predict
Novel Targets
Novel Molecules
Clinical Trials
PandaOmics is a generative AI software designed for therapeutic target and biomarker discovery launched in 2020. It includes more than 20 AI and bioinformatics models, which is produced through a combination of generative AI techniques and human expert validation, and its innovative approach was first introduced in the iPANDA paper published in 2016.
PandaOmics uses in silico pathway activation network decomposition analysis and generative AI approaches to identify novel targets and biomarkers in a variety of therapeutic areas. One of the most characteristic features of PandaOmics is its knowledge graph for target-disease associations, which is generated by transformer-based natural language processing models applied to biomedical information published in scientific literature for the last 30 years. These models are a type of generative AI technology that can understand and generate human-like language. They extract relevant information from sources to create knowledge graphs that can aid in target discovery.
In March 2023, Insiico introduced ChatPandaGPT, an advanced AI chat functionality integrated into PandaOmics' knowledge graph using recent advances in large language models designed to expedite information gathering related to molecular biology, target discovery and drug development.
Chemistry42 is a customizable and fully automated software platform launched in 2020 that integrates generative AI algorithms with computational and medicinal chemistry methods to generate novel molecules with potential drug-like properties, sometimes in a matter of days.
The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks. Insilico's work with generative adversarial networks was first published in 2016 in an article titled "The cornucopia of meaningful leads" in Oncotarget, and was noted in Nature Biotechnology related to the rapid identification of DDR1 kinase inhibitors.
Chemistry42 accesses both structure-based and ligand-based drug design and also has the ability to utilize predicted protein structures, such as those found in AlphaFold. Chemistry42 was designed to be seamlessly integrated with PandaOmics to enable a workflow from novel target identification to de novo small molecule generation and optimization.
InClinico is a generative AI-powered software platform utilizing a data-driven, multimodal forecast for predicting the outcome of Phase II clinical trials launched in November 2022. The platform's prediction engines utilize data from small molecule chemical properties, transcriptomics, text data and clinical trial protocols. InClinico's predictive accuracy has been tested through retrospective, quasi-prospective and prospective validation studies. InClinico's prediction engine achieved a 0.88 ROC AUC in predicting Phase II to Phase III transition in a quasi-prospective setting.
In August 2023, Insilico demonstrated that inClinico can predict the probability of success for Phase II to Phase III clinical trial transitions with a high degree of accuracy, based on multiple validation models over 7 years. The research was published in Clinical Pharmacology and Therapeutics, an authoritative cross-disciplinary journal in experimental and clinical medicine.
Insilico Medicine has announced a number of R&D collaborations with pharmaceutical companies.
In January 2024, Insilico entered into an exclusive licensing agreement with The Menarini Group, a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. granting Stemline the global rights to develop and commercialize a novel, small molecule KAT6A inhibitor designed using Insilico's AI platform, as a potential treatment for hormone sensitive cancers and other oncology indications. The combined value of the deal, including all development, regulatory, and commercial milestones, is over $500 million, followed by royalties up to double digits.
In Sept. 2023, Insilico announced an exclusive global license agreement with Exelixis – granting Exelixis the right to develop and commercialize ISM3091, a potentially best-in-class small molecule inhibitor of USP1, which has emerged as a synthetic lethal target in BRCA-mutated tumors. The agreement included an $80 million upfront fee in exchange for Insilico granting Exelixis an exclusive, worldwide license to develop and commercialize ISM3091 and other USP1 targeted compounds. Insilico will also be eligible to receive future development, commercial, and sales-based milestone payments, as well as tiered royalties on net sales.
Its largest partnership was announced in November 2022, a multi-target collaboration with Sanofi including upfront and target nomination fees of up to $21.5 million and other development- and commercial-based milestones that could total up to $1.2 billion, in addition to royalties.
In January 2022, Insilico Medicine announced a multi-target collaboration with Fosun Pharma, along with co-development of Insilico's QPCTL program, including an upfront payment of $13 million, an equity investment and other development- and commercial-based milestones. Insilico announced that it reached its first clinical milestone in the collaboration with Fosun in Aug. 2023, commencing Phase I studies of ISM8207 for the treatment of advanced malignant tumors.
The Company also has collaborations with Pfizer, Arvinas, APRINOIA Therapeutics, Janssen Pharmaceutical Companies, Astellas Pharma, Syngenta,
Deerfield Discovery & Development, and Taisho.
Insilico Medicine has received numerous industry awards, including being named the #1 biotech company in Fast Company's Most Innovative Companies list (2024); CB Insights' AI 100 (2022), BioCentury-BayHelix East-West Summit's Company of the Year (2022), Frost & Sullivan's Entrepreneurial Company of the Year (in global AI-enabled drug discovery) (2021), Fierce Biotech's Fierce 15 (2019), and Frost & Sullivan's North American Artificial Intelligence for Aging Research and Drug Development Technology Innovation Award (2018).
Hong Kong Office
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Alex Zhavoronkov in Suzhou Robotics Lab
Suzhou Robotics Lab
Feng Ren in Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Suzhou Robotics Lab
Shanghai Office
Media Contact